Carmignac Gestion Buys Shares of 1,575,700 Zoetis Inc. $ZTS

Carmignac Gestion bought a new stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,575,700 shares of the company’s stock, valued at approximately $113,230,000. Zoetis accounts for approximately 1.4% of Carmignac Gestion’s investment portfolio, making the stock its 19th largest position. Carmignac Gestion owned about 0.38% of Zoetis as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. California State Teachers Retirement System lifted its position in Zoetis by 6,680.3% in the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company’s stock worth $3,430,982,000 after buying an additional 47,041,186 shares in the last quarter. J. Stern & Co. LLP increased its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter worth $734,425,000. Flossbach Von Storch SE purchased a new stake in shares of Zoetis during the second quarter worth $302,601,000. Finally, BlackRock Inc. boosted its position in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Stifel Nicolaus lowered their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Finally, Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $107.43.

Zoetis Stock Down 3.0%

Shares of NYSE ZTS traded down $2.25 during mid-day trading on Tuesday, reaching $73.56. 5,656,598 shares of the company traded hands, compared to its average volume of 5,703,784. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a market cap of $30.40 billion, a PE ratio of 12.12, a price-to-earnings-growth ratio of 1.77 and a beta of 0.73. The company’s fifty day moving average is $75.58 and its two-hundred day moving average is $93.26. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $152.12.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company earned $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.